Skip to main content
Full access
Letter to the Editor
Published Online: 1 April 2005

5-Methoxy-N,N-Diisopropyltryptamine-Induced Flashbacks

Publication: American Journal of Psychiatry
To the Editor: The drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has hallucinogenic and mild euphoric properties, similar to those of other tryptamine compounds (1). Hallucinogen-persisting perception disorder is characterized by the transient recurrence of perceptual symptoms experienced while intoxicated with the hallucinogen, often called “flashbacks.” LSD-induced flashbacks are well known. It is also reported that hallucinogen-persisting perception disorder is induced by cannabis and methamphetamine. However, to our knowledge, there are no published reports of 5-MeO-DIPT-induced hallucinogen-persisting perception disorder.
Mr. A, a 35-year-old Japanese man without a previous psychiatric history, was seen with perceptual disturbances. One month before his evaluation, he had stopped using 5-MeO-DIPT because of a so-called bad trip—anxiety, palpitations, auditory oversensitiveness, and visual distortion—after six or seven times using between 15 mg and 30 mg of 5-MeO-DIPT over 5 months. He was bisexual and had used the drug to enhance intercourse with a male partner. A few days before his evaluation, after the announcement of his father’s diagnosis of a brain tumor, his 5-MeO-DIPT-induced phenomena of a “bad trip” returned, although he had not taken 5-MeO-DIPT.
There was no evidence of CNS infection or organic brain disease. Amphetamine was not detected in Mr. A’s urine. He was not clinically depressed. Schizophrenia-like symptoms, such as delusions or auditory hallucinations, were not present. He was given oral risperidone, 1 mg/day. Within 3 days, his perceptual disturbances remarkably decreased, and 7 days later, they had almost completely disappeared. Given his clinical features and history of drug ingestion, we made a diagnosis of hallucinogen-persisting perception disorder induced by 5-MeO-DIPT. Mr. A was discharged 1 month later. Although this medication was maintained for 4 months and then terminated, he has had no relapse.
The disturbances of serotonergic function may be a factor in hallucinogen-persisting perception disorder, although the pathophysiology remains unclear. Regarding the treatment of LSD-induced flashbacks, the choice of medication is still controversial. The use of various agents, including neuroleptics, serotonin reuptake inhibitors (SSRIs), anticonvulsants, and benzodiazepines, has met with limited success (2). Some researchers report that risperidone, which is a serotonin-dopamine antagonist, exacerbates symptoms of hallucinogen-persisting perception disorder (3). Others note that SSRIs exacerbate flashbacks (4). In this case, his perceptual disturbance symptoms responded to risperidone treatment.
For public safety, 5-MeO-DIPT is a controlled substance in several countries. However, it is available in many areas, and the patient obtained it through the Internet quite easily. We are concerned that the abuse of 5-MeO-DIPT may be more widespread than previously thought. We believe that studies are needed to verify the relationship between 5-MeO-DIPT and hallucinogen-persisting perception disorder and to call public attention to the toxicity of 5-MeO-DIPT.

References

1.
Meatherall R, Sharma P: Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 2003; 27:313–317
2.
Strassman RJ: Adverse reactions to psychedelic drugs. J Nerv Ment Dis 1984; 172:577–595
3.
Morehead DB: Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol 1997; 17:327–328
4.
Markel H, Lee A, Holmes RD, Domino EF: LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 1994; 125:817–819

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 815
PubMed: 15800171

History

Published online: 1 April 2005
Published in print: April 2005

Authors

Affiliations

KANAKO SEKIGUCHI, M.D.
KENICHI FUJITA, M.D., Ph.D.
HIROSHI YAMADERA, M.D., Ph.D.
YOSHIHIKO KOGA, M.D., Ph.D.
Tokyo, Japan

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share